CorVel (CRVL) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
20 May, 2026Executive summary
Fiscal year 2026 revenue rose 7% to $959 million, with quarterly revenue up 7% to $249 million year-over-year.
EPS for the year increased 17% to $2.14, and quarterly EPS rose to $0.61 from $0.51 year-over-year.
Net income for fiscal 2026 was $110.3 million, up from $95.2 million in the prior year.
Strong performance in Network Solutions and CERIS health division, aided by one-time post-payment recoveries and increased adoption of prepay/post-pay platforms.
New bookings surged 56% year-over-year, with RFP activity up 20%, supporting future growth.
Financial highlights
Operating margin improved to 15%, up 1.4 percentage points from fiscal 2025.
Gross profit for the quarter increased 9% to $63.0 million, with a 25% gross margin.
General administrative expenses fell by $1.3 million in Q4, reducing G&A as a percentage of revenue from 10.6% to 9.4%.
Free cash flow reached $66 million, a $7 million increase year-over-year.
Cash balance at year-end was $233 million, with no debt.
Outlook and guidance
Multi-year bookings and large payer wins expected to drive revenue and profit growth in the second half of the year.
Ongoing investments in AI, automation, and technology-enabled services to enhance scalability and operational efficiency.
Personnel levels to normalize as automation and AI are deployed, supporting productivity gains.
Strong demand for healthcare payment accuracy and cost management solutions is expected to drive future growth.
Latest events from CorVel
- Revenue and EPS rose, with AI-driven efficiency and strong cash supporting growth.CRVL
Q3 20265 Feb 2026 - Technology-driven care management and financial strength position the firm as a top industry innovator.CRVL
Investor presentation3 Feb 2026 - Revenue up 11.3% and EPS up 10% as AI and new accounts drive growth and efficiency.CRVL
Q1 20252 Feb 2026 - Revenue up 13% and EPS up 39% year-over-year, with strong cash and AI-driven efficiency.CRVL
Q3 20259 Jan 2026 - Director elections, auditor ratification, and a new stock plan headline a governance-focused agenda.CRVL
Proxy Filing1 Dec 2025 - Six directors and the external auditor are up for shareholder vote at the August 2024 meeting.CRVL
Proxy Filing1 Dec 2025 - Shareholders will elect six directors and ratify the auditor, with a focus on governance and diversity.CRVL
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor ratification, and a new stock incentive plan.CRVL
Proxy Filing1 Dec 2025 - Double-digit revenue and EPS growth, expanded AI operations, and a debt-free balance sheet.CRVL
Q4 202524 Nov 2025